Therapy News and Research

RSS

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

ACR updates 39 appropriateness criteria topics and adds five new criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

29 Jun 2012

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could - paradoxically - shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.

29 Jun 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012

Benefits of complementary and alternative medicine for back pain

Got a pain in the neck or back? Relief could be just an adjustment away. In a recent study, "Perceived Benefit of Complementary and Alternative Medicine (CAM) for Back Pain" (Journal of the American Board of Family Medicine, May - June 2010, Vol. 23 No.3), the majority of respondents receiving CAM for back pain reported significant benefits from the various treatments.

29 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Self-managed aphasia therapy after stroke feasible

A pilot study carried out in stroke patients with aphasia suggests that self-managed computer therapy is feasible and practical.

28 Jun 2012

Statin effects may be gender-specific

The benefit of using statins may differ according to gender, show findings from a meta-analysis.

28 Jun 2012

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

The UCLA Heart Transplant Program performed its 2,000th heart transplant surgery earlier this month, becoming the first program in the western United States and only the second in the world to achieve this remarkable milestone.

28 Jun 2012

New medical countermeasures against nuclear threats

Concerns about terrorist attacks, the prospect of a rogue nation using nuclear weapons and the Fukushima power plant accident in Japan are fostering efforts to develop a new family of drugs that everyone hopes will never be used, according to an article in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

28 Jun 2012

Study examines role and biological effects of psychotherapy in breast cancer survivors

In a study published in the current issue of Psychotherapy and Psychosomatics the role and biological effects of psychotherapy in breast cancer survivors is examined.

28 Jun 2012

TB research finds body’s own response helps TB bacteria survive

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children’s Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health threat posed by the disease.

28 Jun 2012

Therapy News and Research

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

ACR updates 39 appropriateness criteria topics and adds five new criteria

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

AASLD, EASL to hold special conference on therapy of HCV

Benefits of complementary and alternative medicine for back pain

Millennium introduces novel pharmacogenetic testing

Bayer receives priority review designation from FDA for regorafenib NDA

Results from Access’ MuGard Phase 4 trial on oral mucositis

Self-managed aphasia therapy after stroke feasible

Statin effects may be gender-specific

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

New medical countermeasures against nuclear threats

Study examines role and biological effects of psychotherapy in breast cancer survivors

TB research finds body’s own response helps TB bacteria survive

Exposure-based CBT for primary PD/AG effectively reduces anxiety and depressive symptoms

Scientists transplant stem cells from patients with limb-girdle muscular dystrophy into mice

Menopausal women may experience fewer hot flashes following physical activity

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News